Mammary tumor cells are required to degrade the surrounding matrix and disseminate in order to metastasize, and both of these processes are controlled by a tumor cell-signaling network that remains poorly defined. MEKK1 is a MAPKKK that regulates both the extracellular signal regulated kinase (ERK1/2) and the c-Jun amino terminal kinase (JNK) signaling pathways. MEKK1 signaling regulates migration through control of cell adhesion and is required for inducible expression of urokinase-type plasminogen activator (uPA). MEKK1-deficient mice with mammary gland-targeted expression of the polyoma middle T antigen (PyMT) transgene develop primary mammary tumors at a rate and frequency similar to wild-type littermates, indicating that MEKK1 deficiency does not affect PyMT-mediated transformation. However, MEKK1À/À mice display significantly delayed tumor cell dissemination and lung metastasis. Delayed MEKK1-dependent tumor dissemination is associated with markedly reduced tumor uPA expression, gelatinase activity, and prolonged tumor basement membrane integrity. siRNA-mediated MEKK1 knockdown inhibits uPA activity, cell migration and invasion in MDA-MB-231 human breast cancer cells. Thus MEKK1 controls tumor progression by regulating both the migration and proteolysis aspects of tumor cell invasiveness. To our knowledge, this is the first example of a MAPKKK that regulates metastasis through control of tumor invasiveness.
Introduction
Mortality in cancer patients is often attributable not to the original tumor, but rather to metastatic disease that arises when primary tumor cells establish new foci at distant sites. Metastatic breast tumors are formed by cells that disseminate from the primary tumor mass to secondary organ environments, therefore two key requirements for metastasis of breast tumors are degradation of the surrounding basement membrane and tumor cell migration (Fidler, 1991; Bogenrieder and Herlyn, 2003) .
Basement membrane components include extracellular matrix (ECM) proteins that are digested by extracellular proteinases, such as plasmin and matrix metalloproteinase (MMP) family members (Stamenkovic, 2000) . Degradation of the ECM surrounding primary tumors would facilitate invasion of tumor cells into the surrounding organ parenchyma, thus MMPs and plasmin activators have been subject to intense study in recent years as potential mediators of tumor cell metastasis. Multiple studies have linked expression of the urokinase-type plasminogen activator (uPA) to tumor invasiveness and progression (Andreasen et al., 1997; Sidenius and Blasi, 2003) . Importantly, uPA protein expression in both the tumor and the surrounding stroma has been shown to be a prognostic indicator of survival in cancers of multiple tissue types, and high expression is associated with poor prognosis (Christensen et al., 1996; Duffy, 2004; Duffy and Duggan, 2004; Manders et al., 2004; Tanaka et al., 2004) . Urokinase-type plasminogen activator cleaves plasminogen to form active plasmin that can degrade ECM components directly, as well as indirectly through activation of MMPs (Lijnen et al., 1998) . MMP activity is increased in many forms of human cancer, and this increase is associated with tumor progression (Westermarck and Kahari, 1999; Egeblad and Werb, 2002) .
Mammary-targeted transgenic expression of polyomavirus middle T antigen (PyMT) results in a mouse model that rapidly produces mammary carcinomas with a high level of uPA expression (Bugge et al., 1998) . PyMT-induced mammary tumors are highly metastatic, with the majority of female mice rapidly developing lung metastasis (Guy et al., 1992; Bugge et al., 1998) , but the incidence of metastasis is significantly reduced by breeding into a plasminogen-deficient background (Bugge et al., 1998) , or a uPA deficient background (Almholt et al., 2005) . Thus, the PyMT model highlights the importance of uPA/plasmin-dependent proteolysis to breast tumor progression.
Inducible uPA expression is strongly dependent upon binding of AP-1 transcription factors to a regulatory sequence upstream of the uPA promoter (D'Orazio et al., 1997; Cirillo et al., 1999) . Mitogen-activated protein kinase pathway signaling regulates both AP-1 activity and uPA expression. The MAPKs ERK1/2 and JNK regulate expression, activation, and stability of AP-1 dimer complexes (Fuchs et al., 1996; Karin et al., 1997) , and we have recently demonstrated that both ERK1/2 and JNK are required for growth factorinduced uPA expression . MEKK1 is a MAPKKK that regulates both JNK and ERK1/2 signaling (Yujiri et al., 1998) , and we have shown that MEKK1 controls uPA expression . Further, we have also demonstrated that MEKK1 controls cell migration, in part through regulation of focal adhesion turnover . Loss of MEKK1-dependent cell migration is not rescued by co-culture with wild-type cells, indicating that this function is independent of secreted uPA activity. Our studies indicated that MEKK1 regulates activity of the intracellular proteinase calpain through control of ERK1/2 activation, and this calpain activity is required for release of adhesion of the trailing uropod from the substrata. As MEKK1 regulates both cell migration and uPA expression, we postulated that MEKK1 promotes tumor cell metastasis, and that ablation of MEKK1 expression would reduce tumor cell metastatic potential. In this work, we demonstrate that MEKK1 gene disruption delays PyMT-induced mammary tumor cell dissemination, and define a mechanism whereby MEKK1 influences metastasis during breast tumor progression.
Results
Loss of MEKK1 inhibits tumor cell invasiveness MEKK1-deficient fibroblasts display inhibited directional migration and have a dramatically reduced capacity to upregulate uPA expression Witowsky et al., 2003) . These observations suggested that MEKK1 knockdown could have a dramatic effect on the metastasis potential of tumor cells. We wanted to test this hypothesis by blocking MEKK1 expression in an invasive tumor cell line and then comparing the metastasis-related functions of these cells to the original cell line. Therefore, we used siRNA to knock down MEKK1 expression in the invasive human breast adenocarcinoma cell line MDA-MB 231. We observed a marked knockdown of MEKK1 protein expression with two different siRNAs that target different regions of the human MEKK1 gene (Figure 1a) . We separated equal amounts of transfected cell lysate total protein by sodium dodecyl sufate-polyacrylamide gel electropheresis (SDS-PAGE) and performed immunoblot analysis with anti-MEKK1 antibodies. Our results displayed in Figure 1a clearly show a dramatic reduction in MEKK1 protein in cells transfected with MEKK1 siRNA but not control siRNA. When these membranes were reprobed with anti-p53 antibodies, the immunoblots showed that neither MEKK1 siRNA altered p53 expression (Figure 1a ). These data indicate that both MEKK1 siRNA sequences dramatically reduced MEKK1 protein expression without directly or indirectly altering expression of p53 that is frequently responsive to off-target siRNA effects (Scacheri et al., 2004) , and are consistent with specific siRNA-mediated MEKK1 knockdown.
Tumor cell invasiveness requires both proteinase activity and tumor cell migration, thus we examined the siRNA-transfected MDA-MB 231 cells to determine if MEKK1 knockdown inhibited these components of tumor cell invasiveness. Loss of MEKK1 expression caused a significant reduction in secreted uPA activity, as media conditioned by MEKK1 siRNA-transfected cells show markedly reduced uPA activity compared to media conditioned by an equal number of control siRNA-transfected cells (Figure 1b) . We also performed chemotaxis assays and found that MEKK1 siRNAtreated tumor cells showed a marked reduction in directed migration toward serum compared to cells transfected with a control siRNA (Figure 1c ). These data indicate that MEKK1 expression affects at least two cellular functions required for tumor metastasis.
As MEKK1 knockdown inhibited both tumor cell migration and uPA expression, we tested the transfected tumor cells to determine if loss of MEKK1 expression would inhibit tumor cell invasiveness. In vitro invasiveness was defined as the ability to penetrate and migrate through a Matrigel-coated membrane. Strikingly, we found that MDA-MB 231 cells transfected with MEKK1 siRNA duplexes were significantly less invasive than those cells that had been transfected with control siRNA (Figure 1d ). These combined data indicate that MEKK1 regulates tumor cell invasiveness, and strongly suggest that MEKK1 produces this effect through control of both uPA expression and cell migration.
Fibroblasts are chief components of mammary stroma and have been shown to be a major source of secreted uPA in mouse mammary tumors (Sieuwerts et al., 1999) . We have previously demonstrated that FGF-2-inducible uPA expression is blocked in MEKK1-deficient mouse embryo fibroblasts . As MDA-MB 231 cells have been shown to secrete growth factors, including FGF-2 and PDGF (Bronzert et al., 1987; el Yazidi and Boilly-Marer, 1995) , we predicted that MDA-MB 231-conditioned media would induce uPA activity in fibroblasts and that uPA activity would be reduced in MEKK1-deficient fibroblasts. We compared the secreted uPA activity of both wild-type and MEKK1-deficient fibroblasts cultured in MDA-MB 231-conditioned media. While both stimuli induce secreted uPA activity, MDA-MB 231-conditioned media treatment results in a striking enhancement of uPA induction compared to serum treatment (Figure 1e ). Consistent with our previous findings, we observed that both serum-inducible and MDA-MB 231-conditioned media-inducible uPA activity is significantly reduced in MEKK1-deficient MEFs (Figure 1e ). These results indicate that MEKK1 controls fibroblast uPA activity in response to tumor cell-secreted factors.
Moreover, this MEKK1-mediated regulation of uPA expression and migration is exerted in both the transformed epithelium and stroma components of the mammary tumor.
Lung metastasis is delayed in MEKK1-deficient mice Our in vitro results using MDA-MB-231 cells were consistent with an essential role for MEKK1 in regulating tumor invasiveness. To test this hypothesis in vivo, we bred MEKK1-deficient mice to a transgenic strain that expresses a PyMT transgene under control of the mouse mammary tumor virus long terminal repeat (MMTV LTR). Targeted expression of PyMT to the mammary tissue leads to rapid development of palpable tumors that progress to aggressive carcinoma and metastasize to the lungs of nearly all transgenic female mice (Guy et al., 1992; Bugge et al., 1998) . We detected palpable tumors Transfected cells were seeded in invasion chambers with Matrigel-coated filters and incubated for 22 h. Cells that migrated through the filters were stained and counted in five randomly selected fields. (e) uPA activity of culture media conditioned by wild-type and MEKK1-null fibroblasts grown in 10% fetal bovine serum (FBS) or in MDA-MB 231 cell-conditioned media (CM). In (b), (c), (d), and (e), the results shown are the mean7s.e.m. of at least three independent experiments, and the statistical significance was determined by Student's t-test. Asterisk indicates Po0.05. In (e), the asterisks denote significant differences between MEKK1 þ / þ and MEKK1À/À fibroblasts in response to serum and in response to MDA-MB-231-conditioned media.
in virgin female transgenic mice by 12 weeks of age. Primary tumor development was monitored in both MEKK1 þ and MEKK1-null transgenic strains, and all PyMT transgenic mice developed palpable mammary tumors at a similar rate and multiplicity (Figure 2a, b) . We examined lung sections from transgenic females at 12 to 20 weeks of age for the presence of metastatic foci (Figure 2c ). Metastases were first detected in the lungs of transgenic females at 16 weeks of age, with 75% of MEKK1 þ mice displaying lung metastases (Figure 2d) . Strikingly, only 25% of MEKK1À/À PyMT transgenic females had visible metastasis at 16 weeks of age, a marked reduction compared to MEKK1 þ mice ( Figure 2d ). This trend continued throughout the remainder of the experiment, as the incidence of metastasis in 20-week-old MEKK1-null mice was reduced compared to MEKK1 þ littermates (50 vs 80%). The metastases observed in MEKK1À/À lungs were morphologically similar to those of wild-type mice (Figure 2c ). At this point both wild-type and MEKK1-deficient mice had developed large primary tumor burden, so the experiment was terminated as per animal care guidelines. These results indicate that despite the similarity with MEKK1-expressing transgenic mice in the growth and number of primary mammary tumors, the development of lung metastases is significantly delayed in MEKK1-deficient mice. The observed delay in lung metastasis could have been due either to inhibited growth of tumor cells in the lungs of MEKK1-deficient mice (inhibited growth in the target organ), or because MEKK1À/À tumor cells broke away from the primary tumor and entered circulation at a later time point than did tumor cells from wild-type mice (inhibited dissemination). To discriminate between these two possibilities, we determined the time point at which tumor cells began to arrest in the lungs. If the tumor cells from MEKK1 þ and MEKK1À/À PyMT transgenic females arrived simultaneously, then our data would have been consistent with inhibited growth of metastases in MEKK1-deficient mouse lungs. Conversely, if MEKK1À/À tumor cells arrived in the lungs at a later time point than in the wild-type mice, it would indicate that MEKK1-deficient breast tumor cells were inhibited in disseminating from the primary tumor.
While we could detect large metastatic lesions by immunohistochemical staining of lung sections (data not shown), detecting individual early lesions or micrometastasis by this method proved far more challenging and was hampered by both low signal and high background staining. Establishing when tumor cells arrested in the lungs required that we improved both the sensitivity and selectivity of our detection assay. To determine the age at which circulating tumor cells were trapped in the lungs, we took advantage of the mammary-specific expression of PyMT to detect tumor cells in lung tissue. We developed an reverse transcriptase-polymerase chain reaction (RT-PCR)-based assay to detect PyMT expression from disseminated tumor cells in lung tissue by using primers specific for PyMT. The sensitivity of the RT-PCR assay was established by detecting PyMT-expressing cells among PyMT-free cells. Using a fibroblast line that had been transfected with a PyMT expression vector, we found that our assay was sufficiently sensitive to detect a single PyMTpositive cell in 10 4 non-transfected cells ( Figure 2e ). We then assessed the specificity of this tumor cell screen with RNA extracted from the left middle lobe from lungs of 20-week-old mice. As predicted, lungs from non-transgenic female mice or male PyMT transgenic littermates did not display detectable levels of PyMT expression, whereas the lungs from a female PyMT transgenic mouse with confirmed metastasis gave a robust signal (Figure 2f ). Thus, the PyMT PCR detection assay is sufficiently sensitive to detect tumor cells in whole lung RNA, and highly specific so as to accurately identify metastasis-free transgenic mouse lungs as negative. The assay was used to screen lung tissue from virgin female PyMT transgenic mice aged from 8 to 20 weeks, and found that by 12 weeks of age, 100% of transgenic MEKK1 þ /À females had PyMTexpressing cells in lung tissue (Figure 2g ). This result indicated that our RT-PCR assay sensitivity enhanced our ability to detect mammary tumor cells in the lungs of mice, enabling us to detect disseminated tumor cells 4 weeks before metastases were visible by histology ( Figure 2d ). Despite this improved sensitivity, tumor cells were detected in the lungs of only 14% (1 of 7) 12-and 14-week-old MEKK1-deficient transgenic mice ( Figure 2g ). These combined data strongly suggest that the difference in detected tumor cells from the lungs of MEKK1-deficient mice was due to the delayed arrival of tumor cells rather than inhibited growth of metastases arising from MEKK1-deficienct tumor cells. With this RT-PCR assay, we detected tumor cells in 100% of all PyMT transgenic mice, both MEKK1 þ /À and MEKK1-deficient, at 16 weeks of age. Therefore, mammary tumor cells arrive at the lungs of MEKK1-deficient mice about 4 weeks later than MEKK1 þ /À mice. The findings indicate that the dissemination of cells from MEKK1À/À mammary tumors is inhibited, but the ability to establish lung metastases is not.
uPA expression is reduced in MEKK1-null tumors Increased uPA expression is associated with progression in a variety of tumors and we have demonstrated that MEKK1 regulates uPA expression in both fibroblasts and MDA-MB-231 cells with siRNA knockdown of MEKK1 expression (Figure 1) . Therefore, the impact of MEKK1 deficiency on uPA expression was assessed in PyMT-induced mammary tumors. Immunofluorescence was used to determine both the level and localization of uPA expression in cryosections of PyMT-induced mammary tumors. Confocal microscopy of the tumor sections revealed uPA to be predominantly expressed in the stroma surrounding tumor cell-filled ducts (Figure 3 ). Three-dimensional reconstruction of multiple images collected through the sample indicated that uPA was highly concentrated in the intratumoral stroma (Figure 3) . This pattern of localization shows that the highest concentration of uPA in these mammary tumors is found in areas adjacent to basement membranes, which would facilitate basement membrane degradation by uPA-dependent proteinase activity.
We then determined if PyMT-inducible mammary tumors from MEKK1-deficient mice displayed decreased uPA expression compared to those from MEKK1 þ /À mice. Although we observed uPA staining in sections from both MEKK1 þ /À and MEKK1À/À mice, uPA expression was markedly reduced in MEKK1-deficient mammary tumors (compare Figure 4a, c) . Indeed, comparison of MEKK1 þ tumor sections to MEKK1-deficient samples revealed that uPA expression was significantly inhibited in the tumors of MEKK1À/À mice ( Figure 4e ). In contrast, the level of MMP-2 expression in MEKK1À/À tumors is indistinguishable from that of tumor sections from MEKK1 þ /À mice ( Figure 4b, d and f). These data clearly indicate that uPA expression is inhibited in the mammary tumors taken from MEKK1-deficient mice, and strongly suggest that uPA-dependent proteolysis proximal to tumor basement membrane would be reduced in MEKK1-null mice.
MEKK1-null tumors have reduced gelatinase activity
As we have shown that uPA expression is reduced in MEKK1-deficient PyMT-induced mammary tumors, it was predicted that uPA-dependent proteolysis also would be reduced in MEKK1-deficient tumors. Active uPA cleaves plasminogen to produce active plasmin, and plasmin subsequently cleaves and activates the secreted proteases MMP-1, 3, 9, 10, 13, and possibly impacts MMP-2 (Lijnen et al., 1998) . Matrix metalloproteinases 2, 3, 9, and 10 have been reported to have gelatinolytic activity, and several reports have linked gelatinase activity to tumor progression (Davies et al., 1993; Bianco et al., 1998; Hamasaki et al., 1998; Itoh et al., 1998; Balduyck et al., 2000) . One predicted consequence of the loss of uPA activity in MEKK1-deficient tumors would be reduced gelatinase activity. Tumor-associated gelatinase activity was assessed in situ by gelatin zymography (Frederiks and Mook, 2004) , in which fresh tumor sections are overlayed with fluorochrome-labeled gelatin ( Figure 5 ). In this assay, the fluorescence of labeled gelatin is quenched until the gelatin is cleaved, thus areas of gelatin proteolysis are indicated by fluorescence. We found that tumor sections from 14-week-old MEKK1-null tumors ( Figure 5 , bottom row) had markedly reduced gelatinase activity compared to tumors from age-matched MEKK1 þ /À mice ( Figure 5, top row) . This reduced proteinase activity of MEKK1-null tumors would be expected to have a profound effect upon the ability of these tumor cells to degrade the basement membrane and invade the surrounding tissue.
Tumor basement membrane integrity is prolonged in MEKK1-deficient mammary glands Since 12 to 14-week-old MEKK1-deficient mice show a dramatically reduced incidence of detectable tumor cells in the lungs compared to MEKK1 þ /À mice, the composition of tumors from this age group was examined for evidence of MEKK1-dependent changes that effect tumor cell dissemination. Assessment of basement membrane integrity by histochemical staining demonstrated a clear morphological difference in tumors from MEKK1 þ /À mice compared to those from MEKK1À/À mice. Microscopic examination of tumor sections from 12-week-old mice revealed that the basement membrane in tumors from wild-type mice were disrupted at multiple sites and generally degraded, whereas tumors from MEKK1À/À mice maintained an intact structure (Figure 6 ). Basement membrane surrounding mammary gland ducts include reticulin MEKK1 deficiency inhibits tumor dissemination BD Cuevas et al fibers, and reticulin-stained mammary tumor sections from MEKK1À/À transgenic mice clearly showed that the basement membrane surrounding tumors was intact ( Figure 6 , bottom row). In contrast, the basement membrane surrounding tumors from 12-week-old MEKK1 þ / À mice was frequently disorganized and difficult to discern ( Figure 6, top row) . At 16-20 weeks of age, this 'ragged' appearance also was observed in tumors from MEKK1À/À mice that developed metastases.
Importantly, the presence of tumor cells in the lungs of 12-week-old wild-type mice was associated with this loss of basement membrane integrity in their tumors (Figures 2 and 6 ), whereas intact basement membranes surrounded the tumors of 12-week-old MEKK1-null mice that did not have detectable tumor cells in their lungs. This observation is consistent with a reduced ability of the MEKK1À/À tumor cells to penetrate the basement membrane, so as to invade the surrounding stroma and disseminate to other organs. Taken together, these data strongly suggest that the delay in the development of lung metastasis observed in MEKK1-deficient mice is due to the prolonged integrity of the basement membranes surrounding mammary tumors. Together with the observed loss of membrane-proximal proteolytic activity, these data indicate that MEKK1-deficient transgenic tumors have a reduced capacity to degrade basement membrane. Moreover, the results are consistent with the hypothesis that MEKK1 regulates mammary tumor metastasis through control of tumor cell invasiveness.
MEKK1 is not required for PyMT-induced primary tumor growth
To further test the hypothesis that MEKK1 regulates metastasis through control of invasiveness, we investigated other possible mechanisms for the delayed metastasis observed from MEKK1À/À PyMT-induced 
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BD Cuevas et al mammary tumors. We did not observe a significant difference in the rate of palpable tumor growth or multiplicity between wild-type and MEKK1-deficient females from 12 to 18 weeks of age (Figure 2a, b) . Whole-mount analysis of the right inguinal mammary gland of 6-week-old (data not shown) and 8-week-old mice (Figure 7a, b) revealed that earlier stage tumor growth also was very similar between the two strains. These data indicated that the delayed metastasis of MEKK1-null mice was not due to a corresponding delay in early tumor growth.
Tumor growth is a function of both cell division and cell death. To confirm our palpation measurements, we determined the number of proliferating and TUNELpositive cells in sections of tumors from 14-week-old wild type and MEKK1À/À mice. Tumor cell proliferation was evaluated in situ by immunohistochemical staining for the mitotic marker phosphorylated histone H3, and cell death was visualized by TUNEL stain. The number of proliferating cells in tumors from MEKK1À/À mice (23.2 cells/mm 2 ) was not significantly different from the number observed in tumors from wild type mice (24.8 cells/mm 2 , P ¼ 0.692). Similarly, the number of TUNEL-positive cells in tumors from the MEKK1À/À (2.63 cells/mm 2 ) and wild-type (2.7 cells/ mm 2 ) mouse strains were not significantly different (P ¼ 0.42). Taken together, these data demonstrate that PyMT transgene-induced tumor growth is independent of MEKK1.
MEKK1-deficient mammary tumor metastasis may also be inhibited by delayed progression of tumor cells to an invasive phenotype required for metastasis. Loss of estrogen receptor (ER) expression and hormone dependence has been shown to indicate the development of a more aggressive tumor phenotype (Lapidus et al., 1998; Lin et al., 2003) . Lin et al. (2003) demonstrated that ER expression changes with the stage of tumor progression in PyMT transgenic mice, making ER a marker by which the stage of progression could be assessed. To determine if the delayed lung metastasis in MEKK1-deficient females was due to a corresponding delay in the development of a more aggressive tumor cell phenotype, we compared the ER level of mammary tumor sections from 12-week-old MEKK1 þ /À and MEKK1À/À transgenic mice. Importantly, these MEKK1 þ /À mice had detectable tumor cells in their lungs (Figure 2e ), whereas the MEKK1À/À mice did not. We found ER levels of the respective tumors to mirror the overall stage suggested by cell morphology, that is, ER distribution was heterogeneous across the sections, and similar in overall expression between tumors from wild type and MEKK1À/À mice of the same age (Figure 7c, d) . Thus, the delay in MEKK1À/À tumor cell dissemination was not due to a similar delay in tumor progression as assessed by ER expression.
H&E-stained mammary tumor sections from 12-weekold mice of both strains likewise revealed a heterogeneous pattern of cellular morphology (Figure 7e, f) . Regions of tumor in which the cell morphology was consistent with high-grade, aggressive carcinoma were present in both wild-type and MEKK1À/À tumors. These regions were characterized by poorly differentiated cells with greater nuclear pleomorphism, consistent with progression (Cardiff et al., 2000) (Figure 7e, f) . These data indicate that the delayed metastasis observed in MEKK1-deficient mice was not due to a corresponding delay in tumor cell progression to a more aggressive phenotype.
Vascularization of the breast tumors was examined to determine if the observed delay in MEKK1-deficient transgenic mouse lung metastasis was due to a reduction in tumor angiogenesis. Immunofluorescence analysis of frozen tumor sections using antibodies to the endothelial marker CD31 (PECAM-1) indicated that the extent of vascularization of tumors from 14-week-old wild type 
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and MEKK1À/À transgenic mice was very similar (Figure 7g, h) . We calculated the density of CD31-postive tissue within the tumor sections and found tumors from MEKK1À/À mice (4.1 mm 2 /cm 2 ) to be statistically indistinguishable (P ¼ 0.8769) from wildtype mouse tumors (3.9 mm 2 /cm 2 ). Thus, the delay in metastasis from MEKK1-null tumors was not due to a difference in tumor vascularity compared to tumors from wild-type mice. Altogether, the data indicate that the observed difference in lung metastasis between wild-type and MEKK1-deficient mice could not be attributed to later onset of tumorigenesis, slower tumor growth, inhibited progression, or inadequate vascularity of primary tumors from MEKK1-deficient mice.
Discussion
Expression of the PyMT transgene in mammary tissue of female mice causes rapid development of aggressive tumors with an incidence of lung metastasis that is essentially 100% (Guy et al., 1992; Bugge et al., 1998) . For metastasis to occur, tumor cells originating from ductal breast carcinomas, such as those induced by PyMT, must first penetrate the basement membrane barrier to invade the surrounding stroma and eventually gain access to the vasculature. This requires degradation of the ECM boundary of the duct and migration of tumor cells, two regulatory functions that are controlled by MEKK1 signaling.
We have previously characterized the mechanisms by which MEKK1 controls cell adherence and migration. The MAPKs ERK1/2 and JNK contribute to the regulation of cell migration (Fincham et al., 2000; Glading et al., 2000; Huang et al., 2003 Huang et al., , 2004 Webb et al., 2004) , and MEKK1 regulates the activity of both ERK1/2 and JNK signaling pathways. We have demonstrated that MEKK1-deficient cells displayed a reduced ability to migrate (Yujiri et al., 2000) and subsequently characterized the migrational defect as being partly due to a loss of MEKK1-dependent ERK1/2 activity , resulting in diminished rear-end detachment and increased cell adherence. MEKK1 deficiency resulted in reduced activation of calpain, an intracellular proteinase required for focal adhesion turnover and detachment of the trailing edge of cells. Further, we found that MEKK1 can localize to focal adhesions, and forms a complex with FAK, thus MEKK1 is spatially well situated to regulate calpaindependent proteolytic turnover of focal adhesion proteins and consequently cell adherence . MEKK1 also associates with Rho family GTPases that regulate cell shape change and migration (Fanger et al., 1997) . Our demonstration that siRNA knockdown of MEKK1 expression inhibits MDA-MB 231 breast tumor cell migration, which mirrors our previous findings in MEKK1À/À mouse embryo fibroblasts, indicates that MEKK1 is indeed a primary MAP3K controlling cell migration.
We have also shown that MEKK1 regulates uPA expression by promoting the formation of AP-1 dimers containing c-Jun that promote uPA expression (Cuevas et al., 2005) . Loss of MEKK1 expression results in increased JunB protein in AP-1 complexes and JunB is strongly inhibitory for uPA promoter activity. MEKK1 signaling thus activates the required AP-1 components and suppresses inhibitory JunB for the control of growth factor-dependent stimulation of uPA gene expression.
uPA is implicated in tumor progression and metastatic growth due to its role in regulating plasmin activity and matrix degradation. Indeed, recent evidence correlates uPA expression to human breast tumor prognosis, and increased uPA expression has been associated with poor overall survival (Sidenius and Blasi, 2003; Manders et al., 2004) , and lower efficacy of tamoxifen therapy for some breast cancers (Meijer-van Gelder et al., 2004) . Further, Schweinitz et al. (2004) recently reported that a small molecule uPA inhibitor strikingly reduced lung foci formation in an experimental metastasis model. These observations indicate that MEKK1 would be predicted to regulate tumor metastasis. Analysis of H&E-stained lung sections taken from mice ranging in age from 12 to 20 weeks demonstrated detectable metastatic lung lesions at 16 weeks of age in most MEKK1 þ /À PyMT transgenic mice. The proportion of 16 week-old MEKK1À/À PyMT transgenic mice with lung metastases was markedly less than the MEKK1 þ /À PyMT transgenics. This pattern was repeated when we tested the lungs of 20-week-old mice. The percentage PyMT transgenic mice in a MEKK1À/À background with lung metastasis remained markedly reduced at 20 weeks compared to MEKK1 þ /À littermates. Our data clearly indicated that loss of MEKK1 expression significantly suppressed and delayed the onset of mammary tumor metastasis in PyMT positive female mice.
The MMTV LTR targets PyMT expression to the mammary gland and has been reported to be occasionally expressed in the salivary glands (Ahmed et al., 2002) , but importantly PyMT is not expressed in normal lung tissue. Therefore, PyMT mRNA detected in the lungs of transgenic females indicates the arrival of mammary tumor cells that have arrested in lung capillary beds in addition to breast tumor metastases. If mammary tumor cells were found to arrive at the lungs of wild-type and MEKK1-deficient mice at the same age, then our data would be consistent with inhibition of tumor cell growth in the MEKK1-deficient lung. However, if tumor cells could only be detected in the MEKK1-deficient lungs later than in wild-type mice, this would indicate that the reduced incidence of lung metastasis in MEKK1À/À mice was due to a delay in tumor cell dissemination to the lungs. The RT-PCR assay we developed to measure the expression of PyMT mRNA provided the necessary sensitivity to discriminate between these possibilities. Strikingly, the incidence of detectable tumor cells in the lungs of 12-and 14-week-old MEKK1À/À mice was significantly reduced compared to that of age-matched MEKK1 þ /À mice.
Since PyMT expression was detected in lungs of all MEKK1 þ /À mice at 12 weeks but only a small percentage of MEKK1À/À mice until 16 weeks, loss of MEKK1 expression must delay tumor cell dissemination to the lungs. This significant delay in dissemination is approximately 4 weeks, which is a marked change relative to 20 weeks of age when the primary tumor burden required the mice to be sacrificed. This means that MEKK1 plays a role in post-transformation tumor progression, and loss of MEKK1 is associated with a significant delay in this progression to metastasis. Our studies indicate that MEKK1-deficient primary tumor cells have a reduced ability to invade into the surrounding tissue and migrate to the vasculature, and thus are delayed in entering circulation. We conclude that MEKK1 regulates metastasis, and PyMT-induced lung metastasis formation is markedly delayed in MEKK1-deficient PyMT transgenic mice.
We investigated alternative explanations for the delay in metastasis observed in MEKK1-deficient transgenic mice. The MEKK1-dependent delay in metastasis was not due to a similar delay in primary tumor development and growth in MEKK1-null mice, nor was it attributable to a difference in tumor cell differentiation, as tumor masses from both MEKK1À/À and MEKK1 þ /À mice displayed areas in which tumor cell morphology was consistent with high-grade, aggressive carcinoma. MEKK1 deficiency also did not influence ER expression, a marker for tumor progression. Thus, lung metastasis from MEKK1À/À PyMT transgenic mammary tumors is delayed even though they resemble wild-type tumors in growth and stage of progression. Further, the MEKK1-dependent delay in metastasis was not due to reduced tumor vascularization or an inability of MEKK1-deficient tumors to induce angiogenesis. Therefore, the delay of metastasis in MEKK1-deficient mice is due to the loss of one or more MEKK1-dependent cellular function(s) that are required for PyMT-induced breast tumors to metastasize efficiently. Our results do not rule out the possibility that MEKK1-deficiency also inhibits extravasation and invasion in the target lung, thus contributing to the delay of metastasis. The marked reduction in lesions observed when Schweinitz et al. (2004) treated fiborsarcoma cells with an uPA inhibitor in an experimental metastasis xenograft model supports this possibility. Inhibition of these functions in our model, however, does not completely block metastasis once primary tumor cell dissemination to the vasculature has commenced, and MEKK1À/À metastases resemble those from wild-type mice (Figure 2c ). Of significance, our results closely resemble those observed in uPA-deficient PyMT transgenic mice. In uPA-deficient transgenic mice, the incidence, latency, growth rate and ultimate tumor burden of PyMTinduced primary mammary tumors was not significantly different from uPA þ / þ littermates, but metastasis was markedly reduced (Almholt et al., 2005) . Mice deficient in uPA downstream target plasminogen also showed a marked reduction in PyMT-induced mammary tumor metastasis (Bugge et al., 1998) . The MMPs that are downstream targets of active plasmin have been intensely investigated as potential targets for therapy aimed at blocking tumor progression (Egeblad and Werb, 2002) . These studies serve to underscore the importance of the uPA/plasmin proteolytic system to tumor progression.
Concurrent with this marked delay in tumor cell dissemination was a striking difference in the morphology of the developing tumors that suggested that the MEKK1-deficient tumors remained encased within a surrounding basement membrane longer than did tumor cells from wild-type mice. The basement membrane forms a barrier to migration and eventual metastasis of tumor cells. Our histological analysis of the tumor sections indicates that basement membrane integrity is significantly prolonged in tumors of MEKK1-null mice, and this would effectively prevent tumor cell dissemination. Our studies indicate that the loss of MEKK1 does not completely inhibit uPA expression, hence uPAdependent basement membrane degradation appears significantly delayed but not completely inhibited in MEKK1À/À mice.
A number of studies show that much of the secreted uPA in breast tumors is stromal in origin, with myofibroblasts being a major contributor to the total tumor uPA (Christensen et al., 1996; Nielsen et al., 1996 Nielsen et al., , 2001 . Indeed, the pattern of uPA expression we have observed in tumor sections is consistent with these studies (Figure 3) . Further, we observed reduced secreted uPA activity from MEKK1-deficient fibroblasts in response to tumor cell-secreted factors (Figure 1e ), suggesting that MEKK1-null stroma cells would have a correspondingly reduced capacity to produce uPA in response to stimuli from tumor cells. This prediction was confirmed when we observed tumor sections from MEKK1-deficient mice to have reduced uPA concentration in the intratumoral stroma. Stroma cell uPA secretion in the intratumoral space would regulate plasmin activity proximal to the basement membrane where it could promote membrane degradation. Therefore, reduced stroma uPA expression would be predicted to reduce basement membrane degradation.
One action of uPA-catalyzed cleavage of plasminogen is the activation of gelatinolytic MMPs, some of which have also been linked to tumor invasiveness (Davies et al., 1993; Bianco et al., 1998; Hamasaki et al., 1998; Itoh et al., 1998; Balduyck et al., 2000) . In addition to the loss of uPA activity in MEKK1À/À tumors, a marked reduction of in situ gelatinase activity in MEKK1À/À tumors as assessed by zymography was also observed, and this would contribute to delayed basement membrane degradation and tumor dissemination. This loss of activity was not due to a general reduction in gelatinase expression, as MMP-2 expression was similar between MEKK1À/À and MEKK1 þ /À tumors. MMP-2 is largely regarded to be AP-1-independent, but AP-1 can influence the transcription of other MMPs. Thus it is possible that MEKK1 regulates MMP expression as well as activity, but further study will be required to define any such role for MEKK1. The data presented in this study do not rule out the possibility of altered expression of gelatinases, but rather reveal that a functional consequence of MEKK1 disruption is a marked reduction of tumor gelatinase activity in situ. Cumulatively, our studies have demonstrated that loss of MEKK1 expression reduces uPA expression in whole tumors, tumor cells and fibroblasts, and that this loss is concurrent with prolonged basement membrane integrity and delayed metastasis in MEKK1À/À PyMT-induced breast tumors.
We conclude that MEKK1 controls both the proteolytic and migration aspects of tumor cell invasion into surrounding tissue. Our data define the role of MEKK1 in control of tumor metastasis as that of a key regulator of both uPA expression and cell migration required for tumor cell invasiveness. In the development of this model, we have demonstrated that MEKK1-deficient mice are viable and fertile, thus we predict that specific MEKK1 inhibition would be relatively well tolerated. We did not observe inhibition of metastatic tumor growth in the lungs, so the utility of MEKK1 inhibition alone as anti-metastasis therapy is likely to be limited. The control of proteinase expression and cell migration is a unique regulatory function for MEKK1 relative to all other MAPKKKs characterized to date, and it is tempting to predict that MEKK1 inhibition may be useful in treating pathologies involving destructive tissue remodeling.
Materials and methods

Mice
The generation of MEKK1 null mice and the development of mouse embryo fibroblasts have been described previously (Yujiri et al., 2000) . FVB/N-TgN mice expressing the PyMT oncogene under control of MMTV LTR (Jackson Laboratory) were crossbred with the MEKK1À/À parental strain 129/SvEv for more than six generations to obtain PyMT/129/SvEv þ /À MEKK1À/À litters. All PyMT-positive mice were heterozygous for the PyMT transgene. The genotyping of PyMT transgenic mice was performed by PCR with the following primers: forward, 5 0 -CGGCGGAGCGAGGAACTGAGGA GAG-3 0 ; reverse, 5 0 -TCAGAAGACTCGGCAGTCTTAGGC G-3 0 . Tumor area was assessed by measuring the length and width of the tumor with calipers. All mouse work was performed in accordance with the Institutional Animal Care and Use Committee guidelines.
Immunofluorescence
Images were captured by a Photometrics digital camera linked to a Zeiss Axiovert 200M microscope. Fresh frozen tumor sections were washed in PBS for 15 min to remove OPD, then permeablized in 0.1% Triton X-100/TBS for 10 min, then washed and blocked with 10% rabbit serum/TBST for 1 h. After washing, sections were incubated with antibodies to CD31 (BD Pharmingen, 1:500), or phospho-histone H3 (Upstate, 5 mg/ml), MMP-2 (Santa Cruz, 1:200) or uPA (Finsen Lab, 1:1000) in block and incubated overnight at 41C. After washing, the cells were incubated with Cy3-conjugated anti-rat antibodies (anti-rabbit for uPA and MMP-2) and 4,6-diamidino-2-phenylindole (DAPI) in block for 2 h. Coverslips were mounted in 90% glycerol/10% Tris pH 8.5. Vascular density was quantified by segmented masking using Slidebook version 4 software (Intelligent Imaging Inc., Denver, CO, USA) to calculate CD31-staining and total section surface area for at least five fields/section. TUNEL assays were performed according to manufacturers (Roche) recommendations. TUNEL, phospho-histone H3, uPA and CD31 data were analyzed by Student's t-test.
Immunohistochemistry
Mammary or lung tissue was fixed in formalin and embedded in paraffin for sectioning. To assess tumor morphology and expression patterns, mammary gland sections were immunostained with antibodies to ER (Santa Cruz, CA, USA) and specific reactivity detected by peroxidase reaction (DAKO EnVision, Carpinteria, CA, USA), then counterstained with Mayer's hematoxylin (Sigma, St Louis, MO). The UNC Lineberger Comprehensive Cancer Center Animal Histopathology CORE facility stained mammary and lung sections with H&E and reticulin stains as per standard protocol.
Invasion assay
Tumor cell invasiveness was assessed by the ability to digest and migrate through a standardized matrix layer toward 4% serum using the Biocoat Matrigel invasion chamber (Becton Dickinson, Bedford, MA) as per manufacturers recommendations.
Detection of tumor cells/metastases in transgenic mouse lungs
The presence of mammary tumor cells in the lungs of PyMT transgenic mice was determined by RT-PCR of cDNA derived from lung RNA. The left middle lobe was snap frozen and RNA extracted using TRIzol (Invitrogen, Carlsbad, CA, USA) as per manufacturer's recommendation. The reverse transcriptase reaction was performed using the Super Script RT kit (Invitrogen), and the resulting PyMT cDNA was then amplified using the primers described above. Visible bands of any intensity were scored as positive for tumor cells. The results from 12-and 14-week-old mice were pooled into two sets designated wild-type and MEKK1À/À, and the statistical significance of the difference between sets was determined by w 2 -analysis. The remaining lung tissue was fixed in formalin and embedded. At least three 0.5 mm sections from each mouse were stained with H&E and scanned by light microscopy for metastatic foci.
Mammary gland whole mount
The right inguinal mammary gland was gently removed from the skin and spread on a glass slide and allowed to attach for several minutes. The tissues were fixed in formalin for 4 h and treated with acetone overnight. The slides were then immersed in 100% ethanol for 1 h, followed by 1-h incubations in 95% ethanol, followed by Mayer's hematoxylin. De-staining consisted of successive 1-h incubations in tap water, acidified 50% ethanol, 70% ethanol, 95% ethanol, 100% ethanol (X2), and xylene (X2).
MEKK1 knockdown by siRNA MDA-MB-231 cells were transfected with siRNA duplexes using the Amaxa nucleofector as per manufacturer's recommendations. This transfection method consistently resulted in approximately 70% transfection efficiency as assessed by green flourescent protein (GFP) expression. In all, 10 6 cells were transfected with 1.6 mg siRNA. Transfected cells were then grown in Liebowitz 15 medium with 8% FBS for 72 h before testing. The siRNA duplex no. 1 sequences are AGUGUACG UUGCUGCUUUA dTdT and UAAAGCAGCAACGUAC ACU dTdT, and the duplex no. 2 sequences are ACACUC CAAUCAUCUUGCU dTdT and AGCAAGAUGAUUGG AGUGU dTdT.
Migration assay MDA-MB-231 cells transfected with MEKK1 siRNA or a control siRNA were suspended in serum-free medium. Chemotaxis was assessed by Transwell (Corning, Corning, NY) assay, wherein 10 5 cells were allowed to migrate through a filter (8 mm pore) toward 4% serum for 5 h, and then migrating cells were stained with Wright's stain and counted as previously described .
In situ zymography Fresh mammary tumors were immediately frozen in OCT freezing compound (Tissue Tek) and 0.5 mm sections were attached to slides and then allowed to dry at room temperature for 1 h. A measure of 1 mg of DQ gelatin (Molecular Probes, Eugene, OR, USA) was dissolved in water and diluted to 1 ml with1% LGT agarose in PBS, pH 7.45 at 371C. 4,6-diamidino-2-phenylindole (DAPI) (0.4 mg/ml) was added to visualize nuclei. The sections were then overlayed with the gelatin mixture, chilled to 41C for 10 min to solidify, and incubated in a humidified chamber at room temperature for 16 h. Images were captured by a Photometrics digital camera linked to a Zeiss Axiovert 200 M microscope.
uPA activity assay Urokinase-specific chromogen S-2444 was purchased from DiaPharma Group Inc. (Columbus, OH, USA). Conditioned media was removed from siRNA-transfected MDA-MB 231 cells or fibroblasts, diluted with S-2444 and buffer (50 mM Tris and 38 mM NaCl), and incubated at 371C for 24 h. Urokinasetype plasminogen activator cleaves the substrate to produce a color change detectable at 405 nm. The samples were compared to an identical set of samples that included 200 mM amiloride to distinguish color change due to tPA activity. MDA-MB 231-conditioned media was harvested from nearly confluent cultures of mitomycin C-treated cells 3 days after plating.
